Fundz

Shionogi to acquire Intrabio for rare disease expansion

PUBLIC · SGIOFOct 05, 2026

Acquiring Company

Shionogi & Ltd

Acquired Company

IntraBio Inc

OsakaAustinBiotechnologyHealth CarePharmaceuticalBiotechnology

Description

Shionogi & Co., Ltd. plans to acquire Intrabio Inc as part of its strategy to expand its portfolio in rare diseases. This acquisition will enhance Shionogi's capabilities in developing therapies for conditions with high unmet medical needs. The move represents a significant step in Shionogi's commitment to innovate in the pharmaceutical field. Further details on the transaction have yet to be disclosed.

Company Information

Company

Shionogi & Ltd

Location

Osaka, Osaka Prefecture, Japan

About

Shionogi & Co., Ltd. is a Japanese pharmaceutical company that focuses on the discovery and development of innovative medicines. With a strong commitment to patient needs, Shionogi specializes in treating diseases with significant unmet medical needs. The company emphasizes long-term sustainability and strategic partnerships to enhance its product offerings.

Fundz sees it the moment Shionogi & Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Daniela
Senior decision-maker at this company
••••••••@••••••••

See Daniela's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Shionogi & Ltd's next move

Learn about Strategic plan

Frequently asked

Who acquired IntraBio Inc?

IntraBio Inc was acquired by Shionogi & Ltd, based in Osaka. The deal was reported on October 5, 2026. Shionogi & Co., Ltd. is a Japanese pharmaceutical company that focuses on the discovery and development of innovative medicines. Shionogi & Ltd is publicly traded (SGIOF) and operates in Biotechnology.

When did Shionogi & Ltd acquire IntraBio Inc?

Shionogi & Ltd's acquisition of IntraBio Inc was reported on October 5, 2026. Shionogi & Co., Ltd. plans to acquire Intrabio Inc as part of its strategy to expand its portfolio in rare diseases. This acquisition will enhance Shionogi's capabilities in developing therapies for conditions with high unmet medical needs. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does IntraBio Inc do?

IntraBio Inc is a private pharmaceutical company located in London, United Kingdom, focusing on drug development and commercialization related to common and rare neurodegenerative diseases, as well as ageing and healthspan. It is privately held, operating in Biotechnology, and is based in Austin.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.